ReviewSeminars in cancer biology2012
Linking epithelial-to-mesenchymal-transition and epigenetic modifications.
Review in Seminars in cancer biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- DPY30 promotes colorectal carcinoma metastasis by upregulating ZEB1 transcriptional expression.Cancer cell international · 2023Article
- Phosphorylation of PHF2 by AMPK releases the repressive H3K9me2 and inhibits cancer metastasis.Signal transduction and targeted therapy · 2023Article
- Chemokine clouding and liver cancer heterogeneity: Does it impact clinical outcomes?Seminars in cancer biology · 2022Review
- Epithelial-Mesenchymal Transition Gene Signature Related to Prognostic in Colon Adenocarcinoma.Journal of personalized medicine · 2021Article
- Identification of an epigenetic prognostic signature for patients with lower-grade gliomas.CNS neuroscience & therapeutics · 2021Article
- Fine-tuning the metabolic rewiring and adaptation of translational machinery during an epithelial-mesenchymal transition in breast cancer cells.Cancer & metabolism · 2020Article
- Review
- Epigenetic Modifications of the Liver Tumor Cell Line HepG2 Increase Their Drug Metabolic Capacity.International journal of molecular sciences · 2019Article
- NatD promotes lung cancer progression by preventing histone H4 serine phosphorylation to activate Slug expression.Nature communications · 2017Article
- Hypoxia-Inducible Histone Lysine Demethylases: Impact on the Aging Process and Age-Related Diseases.Aging and disease · 2016Review
- Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications.Molecular cancer · 2016Review
- An integrative pan-cancer-wide analysis of epigenetic enzymes reveals universal patterns of epigenomic deregulation in cancer.Genome biology · 2015Article
- Quantitative proteomic analysis of histone modifications.Chemical reviews · 2015Review
- Role of epithelial mesenchymal transition in prostate tumorigenesis.Current pharmaceutical design · 2015Review
- ASPP2 controls epithelial plasticity and inhibits metastasis through β-catenin-dependent regulation of ZEB1.Nature cell biology · 2014Article
- HIV-associated disruption of tight and adherens junctions of oral epithelial cells facilitates HSV-1 infection and spread.PloS one · 2014Article
- Increased macroH2A1.1 expression correlates with poor survival of triple-negative breast cancer patients.PloS one · 2014Article
- Helicobacter pylori CagA: From Pathogenic Mechanisms to Its Use as an Anti-Cancer Vaccine.Frontiers in immunology · 2013Review
- Epigenetic coordination of signaling pathways during the epithelial-mesenchymal transition.Epigenetics & chromatin · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Cancer, as well as other human disorders, has long been considered to result from the consequence of genetic mutations in key regulatory genes that reside in pathways controlling proliferation, cellular differentiation, DNA damage and repair. In the case of cancer, mutations are well documented to arise in key oncogenes and critically important tumor-suppressor genes as part of the disease progression process. In addition to more accepted, genetic mutations, a rapidly increasing body of evidence supports the general view that profound alterations also occur in 'epigenes', whose products serve to define the 'epigenetic landscape' of tumor cells. Aberrant changes in epigenetic mechanisms such as DNA methylation, histone modifications and expression of micro RNAs play an important role in cancer and contribute to malignant transitions. Here we review recent studies linking epigenetic mechanisms to epithelial-to-mesenchymal transition as defined in normal processes, as well as abnormal transitions that lead to oncogensis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.